Dabur Pharma is all set to launch Nanoxel, its indigenously developed nanotechnology based new drug delivery system for cancer formulation paclitaxel in the Indian market. |
Nanoxel is a novel paclitaxel formulation in which the drug is delivered as nano micelles using a polymeric carrier. The company has received necessary regulatory clearance and is to make an official announcement on Thursday. |
|
Dabur's achievement turns significant as nanotechnology is still an emerging scientific discipline world over. |
|
It deals with handling matter at a nanometer scale (1 -100 nanometers,one nanometer being equal to 1 × 10 -9 of a meter), that is, at the atomic and molecular levels of particles for varied applications including drug delivery. |
|
It was in early 2005 the United States Food and Drugs Administration (USFDA), for the first time, approved a nanoparticulate formulation of the widely used anti-cancer drug paclitaxel. |
|
The medicine Abraxene was delivered using the protein albumin instead of the conventional chemical solvent. |
|
Dabur oncology products are currently available in more than 40 countries. It has leadership position in many of the key markets and has recently entered the US market through USFDA approvals for two of it products, carboplatin injection and paclitaxel injection. |
|
The company plans to register many more products in US and Europe. |
|
The company has oncology medicine manufacturing facilities in UK and India. Its new manufacturing facility at Baddi, Himachal Pradesh is expected to commence commercial production soon. |
|
In a separate development, Dabur India, the flagship company of the Dabur group,informed BSE that Dabur International Ltd, its wholly owned subsidiary has promoted "Naturelle LLC", a subsidiary firm in Ras Al Khaimah, UAE. |
|
The new subsidiary is to get into trading and manufacturing of nutraceuticals, foodstuffs and other personal care products of the company. |
|
|
|